Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

I-Mab Approved to Start US Trials of Immunotherapy for Solid Tumors

publication date: Jan 22, 2019

Shanghai's I-Mab Biopharma announced that its novel CD73 antibody (TJD5), an immunotherapy, was cleared to start Phase I trials in the US. TJD5, the second I-Mab candidate to begin US clinical trials, will be tested in patients with advanced solid tumors. The IND application was filed by I-Mab's US partner, Tracon Pharma of San Diego. In November 2018, the two companies agreed to share US development costs of I-Mab's TJD5 and up to five unspecified bi-specific candidates. More details....

Stock Symbol: (NSDQ: TCON)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.